PE20061199A1 - Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solida - Google Patents

Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solida

Info

Publication number
PE20061199A1
PE20061199A1 PE2006000103A PE2006000103A PE20061199A1 PE 20061199 A1 PE20061199 A1 PE 20061199A1 PE 2006000103 A PE2006000103 A PE 2006000103A PE 2006000103 A PE2006000103 A PE 2006000103A PE 20061199 A1 PE20061199 A1 PE 20061199A1
Authority
PE
Peru
Prior art keywords
solid pharmaceutical
halogen
composition
pharmaceutical preparation
hydroxyl
Prior art date
Application number
PE2006000103A
Other languages
English (en)
Inventor
Hiroaki Yazaki
Hiroshi Ikuta
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of PE20061199A1 publication Critical patent/PE20061199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES HALOGENO, HIDROXILO, ALCOXI C1-C5, ALQUILO C1-C5, ENTRE OTROS; R2 ES H, HALOGENO, HIDROXILO, ALCOXI C1-C5, ENTRE OTROS; R3 Y R4 SON CADA UNO H, HALOGENO, HIDROXILO, ALCOXI C1-C5, ENTRE OTROS; X ES O, S; Y ES -CR5R6-; R5 Y R6 SON CADA UNO H, HALOGENO, ALQUILO C1-C10 SUSTITUIDO O NO, ENTRE OTROS; W ES H, ACILO DERIVADO DE AMINOACIDOS QUE OCURREN NATURALMENTE, ENTRE OTROS; Z ES H, ALQUILO C1-C10 SUSTITUIDO O NO CON HALOGENO, HIDROXILO HIDROXIALQUILO C1-C5, ENTRE OTROS. UN COMPUESTO PREFERIDO ES: SAL DE ACIDO BENCENOSULFONICO DE (2S,4S)-2-CIANO-4-FLUORO-1-[(2-HIDROXI-1,1-DIMETIL)ETILAMINO]ACETILPIRROLIDINA. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN ESTABILIZANTE SELECCIONADO ENTRE AZUCARES Y ALCOHOLES DE AZUCAR QUE REDUCE LA DESCOMPOSICION DEL COMPUESTO, Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA DIPEPTIDILPEPTIDASA IV (DPPIV) UTILES EN EL TRATAMIENTO DE DIABETES TIPO 2
PE2006000103A 2005-01-28 2006-01-24 Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solida PE20061199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005022193A JP2008024592A (ja) 2005-01-28 2005-01-28 シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法

Publications (1)

Publication Number Publication Date
PE20061199A1 true PE20061199A1 (es) 2006-11-18

Family

ID=36570928

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000103A PE20061199A1 (es) 2005-01-28 2006-01-24 Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solida

Country Status (6)

Country Link
JP (1) JP2008024592A (es)
AR (1) AR052197A1 (es)
DO (1) DOP2006000019A (es)
PE (1) PE20061199A1 (es)
TW (1) TW200637815A (es)
WO (1) WO2006080412A2 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
TW583185B (en) * 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
GB0115517D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
TW200401635A (en) * 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof
EA007613B1 (ru) * 2002-08-29 2006-12-29 Тайсо Фармасьютикал Ко., Лтд. Бензолсульфонатная соль (2s,4s)-1-циано-4-фтор-1-[(2-гидрокси-1,1-диметил)этиламино]ацетилпирролидина
HU227684B1 (en) * 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
RU2766487C2 (ru) * 2004-01-20 2022-03-15 Новартис Аг Композиция и способ прямого прессования

Also Published As

Publication number Publication date
WO2006080412A2 (en) 2006-08-03
AR052197A1 (es) 2007-03-07
WO2006080412A3 (en) 2006-09-21
JP2008024592A (ja) 2008-02-07
DOP2006000019A (es) 2006-07-15
TW200637815A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
UA109774C2 (uk) Кристалічні форми саксагліптину та процес його одержання (варіанти)
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
PE20020707A1 (es) Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
UY27317A1 (es) Resolución de sal quiral
NO20081212L (no) Xantinderivater som selektive HM74A agonister
BR122017021516B8 (pt) processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
RS20050939A (en) Pyrido/2,1-a/isoquinoline derivatives as dpp-iv inhibitors
PE20040450A1 (es) Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
BR0312975A (pt) Forma cristalina de agonista de receptor adrenérgico ß2
BRPI0314325B8 (pt) derivados de aza-bicicloalquila, seu uso, seu processo de preparação e composição farmacêutica que os compreende
BRPI0520252A2 (pt) método de desacilar sucralose-6-éster
TW200517389A (en) Biaryloxymethylarenecarboxylic acids
BR0308993A (pt) Métodos para desacilação aquosa estabilizada por tampão
PE20060240A1 (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
BR0313831A (pt) Sais benzenossulfonato de derivados de 4-flúor-2-cianopirrolidina
AR087302A1 (es) Derivados aza heterociclicos sustituidos
Lecerclé et al. Bacterial transferase MraY inhibitors: Synthesis and biological evaluation
ES2206078A1 (es) Proceso para la preparacion de gabapentina.
BRPI0512522A (pt) processo para a preparação de sal de sódio de esomeprazol, composto, formulação farmacêutica, e, método de tratamento
HUP0002754A2 (hu) (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanol-hemiszulfát, eljárás előállítására, ezt tartalmazó gyógyszerkészítmény, valamint intermedierek
PE20061199A1 (es) Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solida
PE20030617A1 (es) Aminoacidos, procedimiento para su preparacion y medicamentos que los contienen
PT1257552E (pt) Derivados de xantina, intermediarios e aplicacao ao tratamento de osteoporose

Legal Events

Date Code Title Description
FX Voluntary withdrawal